Abstract
Aim Thyroid transcription factor -1 (TTF1) is a useful immunohistochemical (IHC) marker for diagnosis of primary lung tumours including differential diagnosis between primary lung adenocarcinoma (AdCa) and mesothelioma (MM). Different TTF1 monoclonal antibodies (MoAbs) are available. The clone SP141 achieved the highest score in the 2014 RCPA QAP. Most published studies used the 8G7G3/1 MoAb and inconsistencies in labelling between different antibodies have been described. Our study compared the performance of 8G7G3/1 and SP141 TTF1 MoAbs in primary AdCa and squamous cell carcinoma (SCC) of lung, and MM. Methods We examined IHC labelling in 83 cases of MM (17 sarcomatoid, 66 epithelioid), 13 poorly differentiated SCCs and 35 AdCas. Results All AdCas labelled with both the SP141 and 8G7G3/1 MoAbs. All MMs and SCCs were negative with 8G7G3/1, but 7/17 sarcomatoid, 0/66 epithelioid MMs and 6/13 SCCs were positive with SP141. Discussion TTF1 expression is useful for diagnosis of primary lung AdCas, but different antibodies have different performance profiles, which may have clinical implications and must be taken into account.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
